Comment on Stefan MASLD as Complication of Diabetes



Stefan’s article offers a timely synthesis of emerging evidence on the relationship between type 2 diabetes and metabolic dysfunction–associated steatotic liver disease (MASLD) (1). As MASLD continues to gain prominence within metabolic medicine, several conceptual and therapeutic aspects merit further clarification—not to challenge the clinical relevance highlighted in the article but, rather, to outline a broader framework that more fully integrates hepatology and diabetology.



Source link